NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 16:36இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
CRISIL Assigns 'BB+/Stable/A4+' Rating to Nureca's Rs 80 Cr Bank Facilities
CRISIL Ratings has assigned ratings of 'CRISIL BB+/Stable' to Nureca Limited's proposed long-term fund-based facilities of Rs 20 crore and 'CRISIL A4+' to proposed short-term letter of credit facilities of Rs 60 crore, covering a total of Rs 80 crore in bank loan facilities. The rating agency highlighted a healthy financial risk profile with low leverage and an adjusted net worth of around Rs 179 crore as of March 31, 2026. CRISIL noted that operating profitability remains modest at 6.2% in FY26 and 8.5-9% in H1 FY27, constrained by trading operations accounting for 70-75% of revenue. Liquidity is categorized as adequate, supported by cash and cash equivalents of Rs 71 crore as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுCRISIL assigned fresh credit ratings of 'CRISIL BB+/Stable' and 'CRISIL A4+' on total bank loan facilities of Rs 80 crore.
ஏன் இது முக்கியம்Enables the company to formalize banking channels and letter of credit limits to fund procurement, while providing independent credit assessment on its liquidity and debt service capability.
Total rated bank facilities: Rs 80 croreRated facilities vs TTM revenue: ~52.3%Cash and cash equivalents (Sep 30, 2026): Rs 71 croreH1 FY27 revenue: Rs 99 crore
📅 குறுகிய காலம்Neutral market impact expected as these are newly assigned ratings for proposed facilities without an upgrade or downgrade.
📈 நீண்ட காலம்Reflects an improving balance sheet with negligible debt, but structural margin expansion depends on shifting the revenue mix from trading (70-75%) to in-house manufacturing.
⚠ அபாய எச்சரிக்கைகள்
Trading business accounts for 70-75% of sales, capping operating margin expansion.
CRISIL highlights working-capital intensity due to large inventory requirements.
👀 கவனிக்க வேண்டியவை
Track whether operating margins remain above 8% in upcoming quarterly results, as CRISIL cited an operating margin drop below 5% as a primary downward rating trigger.
Q2 revenue up 55% YoY to ₹58.53 cr, highest quarterly revenue in 20 quarters
Nureca reported its Q2 FY27 unaudited consolidated results, achieving a 55% YoY revenue growth to ₹58.53 crore from ₹37.74 crore, marking its highest quarterly sales in 20 quarters. Operating profit grew 60% YoY to ₹5.23 crore, while Profit After Tax (PAT) grew 12% YoY to ₹4.05 crore with EPS at ₹4.25. For H1 FY27, revenue reached ₹98.87 crore (up 37% YoY) and PAT surged 60% YoY to ₹7.12 crore, exceeding the entire FY26 annual net profit of ₹2.09 crore. The growth was led by a 55% surge in online sales (accounting for 88% of revenue) and 90% YoY expansion in offline distribution.
உச்சம் நம்பிக்கை
என்ன மாறியதுNureca posted its highest top-line in 5 years alongside 60% growth in operating profit for Q2 FY27.
ஏன் இது முக்கியம்Demonstrates operating leverage and top-line recovery, with H1 FY27 PAT already significantly higher than full-year FY26 PAT while remaining virtually debt-free.
Q2 FY27 Revenue: ₹58.53 கோடிQ2 வருவாய் vs TTM வருவாய்: ~38.3%செயல்பாட்டு லாபம்: ₹5.23 கோடிProfit After Tax: ₹4.05 கோடிH1 FY27 PAT: ₹7.12 கோடிE-commerce revenue share: 88%
📅 குறுகிய காலம்Likely to generate positive market sentiment given the sharp top-line acceleration and margin leverage ahead of the festive/winter peak season.
📈 நீண்ட காலம்Validates the digital-first multichannel strategy; sustainability depends on maintaining profitability amidst platform commissions and offline channel expansion costs.
⚠ அபாய எச்சரிக்கைகள்
High channel concentration with 88% sales coming from e-commerce platforms
Increased working capital tied up in inventory ahead of the winter season
👀 கவனிக்க வேண்டியவை
Track whether working capital normalizes after the festive season and monitor EBITDA margin sustainability as channel expansion into offline continues.
Q1 FY27: ₹40.3 Cr Revenue, Highest in 16 Quarters; PAT Turns Positive at ₹3.1 Cr
Nureca reported a strong operational turnaround in Q1 FY27, achieving its highest quarterly revenue in four years at ₹40.3 Cr, an 18% YoY increase. The company returned to profitability with a PAT of ₹3.1 Cr, recovering from a ₹6.09 Cr loss in the preceding quarter (Mar 2026). A key highlight is the company's liquidity, with ₹110 Cr in net cash and investments, which represents approximately 37% of its current market capitalization of ₹299 Cr. The shift toward in-house manufacturing is progressing, now contributing 27% of total revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully pivoted from a loss-making quarter to its highest sales and profitability in 16 quarters, backed by a debt-free balance sheet.
ஏன் இது முக்கியம்The turnaround validates Nureca's strategy of reducing import dependence through domestic manufacturing and leveraging its 'Dr Trust' brand across omnichannel platforms.
📅 குறுகிய காலம்The stock may see positive momentum as the market reacts to the sharp recovery in profitability and the strong cash position.
📈 நீண்ட காலம்The transition to a manufacturing-led model and the expansion of the Punjab facility could structurally improve margins and reduce supply chain risks over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
High reliance on e-commerce marketplaces (>93% sales)
Platform concentration risk
High P/E ratio of 143.4 relative to historical earnings
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the new medical device facility at Sundran, Punjab, and track if the operating margin (currently 8.7%) continues to expand as manufacturing-led growth replaces the pure trading model.
CEO Aryan Goyal Resigns Following Family Settlement Agreement
Mr. Aryan Goyal has resigned as Whole-time Director and CEO of Nureca Limited, effective July 01, 2026. This departure is a result of a Family Settlement Agreement dated June 17, 2026, which includes the transfer of his entire shareholding to Mr. Saurabh Goyal. The transition comes at a time when the company reported a net loss of ₹6.09 Cr in the March 2026 quarter and maintains a thin TTM operating margin of 0.1%. Investors should note that the exit is structural rather than performance-based, though leadership stability is critical given the recent quarterly volatility.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe CEO and Whole-time Director is stepping down and exiting his equity stake in the company due to a private family settlement.
ஏன் இது முக்கியம்Leadership changes in small-cap companies (TTM Revenue ₹147 Cr) can lead to shifts in strategic execution, especially as the company navigates low profitability (ROCE 2.0%) and high reliance on e-commerce platforms.
Effective Date of Cessation: ஜூலை 01, 2026Family Settlement Date: ஜூன் 17, 2026TTM வருவாய்: ₹147 கோடிMar 2026 Net Profit/Loss: ₹-6.09 கோடிTTM Operating Margin: 0.1%
📅 குறுகிய காலம்The stock may see neutral to cautious sentiment as the market digests the exit of a key promoter-director and waits for clarity on the new leadership structure.
📈 நீண்ட காலம்The consolidation of shareholding under one family member may streamline decision-making, but the company must demonstrate a path back to consistent profitability after the Mar 2026 loss.
⚠ அபாய எச்சரிக்கைகள்
Management transition risk
High reliance on e-commerce marketplaces (>93% sales)
Recent quarterly net loss
👀 கவனிக்க வேண்டியவை
Monitor the official appointment of a successor CEO and any subsequent changes in the 'Digital First' strategy or product portfolio management under the consolidated leadership of Saurabh Goyal.
Nureca's Dr Trust 360 Crosses 2.4 Million Users; Launches AI Health Analytics Suite
Nureca Limited has reached a significant milestone with its Dr Trust 360 platform surpassing 2.4 million registered users. The company is expanding its digital ecosystem by launching 'Dr Trust Intelligence,' an AI-powered analytics suite that provides personalized health insights and trend detection. This new feature is positioned as a premium subscription service, indicating a strategic shift towards recurring digital revenue. Additionally, the company emphasized its data security by hosting health data on Indian servers to comply with local regulations.
முக்கிய அம்சங்கள்
Dr Trust 360 platform reached a milestone of 2.4 million registered users.Launched 'Dr Trust Intelligence,' an AI-driven suite for body-composition analysis and diet plans.New 8-electrode smart scales claim up to 98% DEXA-level accuracy for key health metrics.Monetization strategy introduced through premium subscriptions on Android and iOS apps.Nureca's total customer base stands at over 1.86 crore (18.6 million) across its brands.
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of the new premium AI subscription service, as it represents a high-margin revenue stream compared to traditional hardware sales.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Nureca Promoters Sign Family Settlement; Saurabh Goyal to Consolidate 68.09% Stake
Nureca Limited has been informed of a Family Settlement Agreement (FSA) among its promoter group members to re-align ownership and management. Under the agreement, Mr. Aryan Goyal and Ms. Payal Goyal will transfer their entire 33.74% stake to the sole promoter, Mr. Saurabh Goyal. This will increase Saurabh Goyal's individual holding from 34.35% to 68.09%, consolidating control. Additionally, Mr. Aryan Goyal will resign from his roles as CEO and Director of the company.
முக்கிய அம்சங்கள்
Saurabh Goyal to increase stake from 34.35% to 68.09% via inter-se transfer of 32,19,113 sharesMr. Aryan Goyal and Ms. Payal Goyal to exit their combined 33.74% shareholding completelyMr. Aryan Goyal to step down from the position of CEO and resign as a DirectorThe transaction is exempt from SEBI SAST open offer obligations under Regulation 10(1)(a)
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the CEO's exit on company operations and the subsequent transition in leadership. While the consolidation of control under the Chairman & MD may streamline decision-making, the loss of a key executive warrants a cautious watch.
Mr. Saurabh Goyal, a promoter and director of Nureca Limited, acquired 60,842 equity shares through an off-market transaction on June 9, 2026. The total value of this acquisition is approximately Rs 1.44 crore. This purchase has increased his individual shareholding from 33.72% to 34.35%. Promoter buying is generally viewed as a positive signal indicating confidence in the company's future prospects.
முக்கிய அம்சங்கள்
Promoter Saurabh Goyal acquired 60,842 shares via an off-market transaction.The total transaction value is approximately Rs 1.44 crore (Rs 1,43,70,880).The promoter's stake increased by 0.63%, moving from 33.72% to 34.35%.The transaction was reported under SEBI Prohibition of Insider Trading Regulations.
👀 கவனிக்க வேண்டியவை
Investors should take this as a sign of promoter confidence in the company's valuation. While positive, it is advisable to monitor upcoming quarterly results to ensure fundamental performance aligns with this insider sentiment.
Nureca Limited Revises Incremental Capex Upward to ₹128 Crores for Expansion
Nureca Limited has issued a corrigendum to its previous board meeting outcome, increasing the planned incremental capital expenditure (capex) from ₹100 crores to ₹128 crores. This investment is specifically earmarked for plant and machinery to manufacture medical devices, healthcare consumables, and hygiene products at its Punjab facility. Furthermore, the board has confirmed the approval for purchasing additional land adjacent to its current site in Dera Bassi for future expansion. This revision reflects a 28% increase in the initially reported capex commitment, signaling a more robust growth plan.
முக்கிய அம்சங்கள்
Incremental capex revised from ₹100 crores to ₹128 crores to rectify a typographical error.Investment focused on manufacturing medical devices and healthcare consumables in Dera Bassi, Punjab.Board approved the purchase of additional land adjoining the existing industrial site for future growth.The expansion targets high-growth segments including hygiene products and medical consumables.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's debt-to-equity ratio and funding sources for this ₹128 crore investment. The increased capex commitment is a positive signal for long-term capacity building and revenue potential.
Nureca Ltd Approves ₹100 Cr Capex and Appoints Chander Kant as New CFO
Nureca Limited has announced a significant expansion plan involving an incremental capex of up to ₹100 crores for manufacturing medical devices and healthcare consumables in Punjab. The company is undergoing a leadership transition with Mr. Chander Kant appointed as the new CFO, effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Additionally, the board has secured leadership continuity by re-appointing the CEO and Managing Director for three-year terms and approving the acquisition of additional land for future growth.
முக்கிய அம்சங்கள்
Approved incremental capex of up to ₹100 crores for plant and machinery at the Sundran, Punjab facility.Appointed Mr. Chander Kant as CFO and Key Managerial Personnel effective June 27, 2026.Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for further 3-year terms starting in 2027 and 2026 respectively.Approved the purchase of additional land adjoining existing industrial land for future expansion needs.Accepted the resignation of outgoing CFO Mr. Naresh Gupta, effective June 26, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the ₹100 crore capex as a strong growth indicator for the company's manufacturing capabilities, while monitoring the smooth transition of the new CFO and the execution of the expansion project.
Nureca Approves ₹100 Cr Capex for Expansion and Announces Major Management Changes
Nureca Limited has approved a significant incremental capital expenditure of up to ₹100 crores to expand its manufacturing capacity for medical devices and healthcare consumables in Punjab. The company is undergoing a leadership transition with Mr. Chander Kant appointed as the new CFO effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Furthermore, the board has secured management continuity by re-appointing the CEO and MD for three-year terms and adding Ms. Smita Goyal as a Whole Time Director. The 10th Annual General Meeting is scheduled for July 28, 2026.
முக்கிய அம்சங்கள்
Approved incremental capex of up to ₹100 crores for manufacturing medical devices and hygiene products at the Sundran, Punjab facility.Appointed Mr. Chander Kant as CFO and KMP effective June 27, 2026, succeeding the outgoing CFO Mr. Naresh Gupta.Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for three-year terms starting May 2027 and September 2026 respectively.Authorized the purchase of additional land adjoining existing industrial plots in Dera Bassi for future expansion needs.Fixed the 10th AGM date for July 28, 2026, with the share transfer books closing from July 22 to July 28, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the ₹100 crore capex commitment as a strong signal of growth and a move towards backward integration in manufacturing. Monitor the transition of the new CFO and the progress of the facility expansion for impact on future margins.
Nureca FY26 Turnaround: Operating Profit at ₹8.5 Cr; Q4 PAT Impacted by Investment Losses
Nureca Limited achieved a significant operational turnaround in FY26, posting an operating profit of ₹8.5 Cr compared to a loss of ₹7.5 Cr in FY25. Annual revenue grew 34% YoY to ₹146.96 Cr, driven by its digital-first strategy where 90% of sales are online. However, Q4 FY26 saw a net loss of ₹6.1 Cr primarily due to non-cash fair value changes in investments. The company remains debt-free and is aggressively expanding its offline distribution network and in-house manufacturing capabilities.
முக்கிய அம்சங்கள்
FY26 Revenue increased by 34% YoY to ₹146.96 Cr from ₹109.7 Cr in FY25.Operational turnaround achieved with FY26 operating profit of ₹8.5 Cr vs a loss of ₹7.5 Cr in the previous year.Q4 FY26 PAT was a loss of ₹6.1 Cr due to 'Fair value changes and net loss on investment' under Ind AS compliance.Company remains debt-free and completed a share buyback worth ₹15.7 Cr during the period.Offline footprint expanded to 285+ distributors across 29 states and Union Territories.
👀 கவனிக்க வேண்டியவை
Investors should focus on the core operational turnaround and rising revenue, while discounting the Q4 PAT loss which was driven by non-operating investment volatility. Monitor if the company can maintain operating margins above 5% while scaling its offline distribution and in-house manufacturing.
Nureca Deposits ₹57.13 Lakh with DRI Over Product Classification Dispute
Nureca Limited has informed the exchanges regarding a hearing with the Directorate of Revenue Intelligence (DRI) concerning product classification under the Customs Act, 1962. Following the hearing held on May 13, 2026, the company has made a pre-deposit of INR 57,12,811 with the authorities. The company clarified that this payment is made without prejudice to its legal rights and does not constitute an admission of liability. As of now, no formal order has been issued by the DRI, and the company is awaiting further developments.
முக்கிய அம்சங்கள்
Hearing conducted by DRI on May 13, 2026, regarding product classification under Section 108 of the Customs Act.Company made a pre-deposit of INR 57,12,811 (approximately ₹57.13 lakh) during ongoing proceedings.The payment is made without prejudice and does not represent an admission of liability by Nureca.No formal order has been issued by the DRI as of the announcement date of May 24, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the final order from the DRI, as an adverse ruling on product classification could lead to higher import duties and impact future margins. While the current deposit amount is manageable, the final classification will determine the long-term tax liability for the company's product range.
Nureca Promoters' Stake Rises to 68.09% Following Share Buyback Extinguishment
Nureca Limited's promoter group has seen their collective shareholding increase from 64.97% to 68.09%. This change is a direct result of the company's recent buyback program, which concluded with the extinguishment of 4,58,255 equity shares on January 07, 2026. While the absolute number of shares held by the promoters remained unchanged at 64,97,176, the reduction in the total share capital base led to a 3.12% increase in their voting rights. This transaction is exempt from open offer requirements under SEBI (SAST) Regulation 10(4)(c).
முக்கிய அம்சங்கள்
Promoter group stake increased by 3.12% to reach a total of 68.09% of the company.Total equity share capital reduced from 1,00,00,175 to 95,41,920 shares post-extinguishment.A total of 4,58,255 shares, representing approximately 4.58% of the pre-buyback capital, were extinguished.Individual promoter Saurabh Goyal's stake increased from 32.17% to 33.72% without purchasing new shares.The disclosure was filed under Regulation 10(6) of SEBI (SAST) Regulations, 2011.
👀 கவனிக்க வேண்டியவை
The increase in promoter stake via buyback is a positive signal of management's confidence in the company's valuation. Investors should look for improvements in Earnings Per Share (EPS) as a result of the reduced share count in future financial reports.
Nureca Q3 FY26: PAT Surges 233% YoY to ₹3.7 Cr; Revenue Up 27% to ₹54 Cr
Nureca Limited reported a strong financial performance for Q3 FY26, with revenue growing 27% YoY to INR 540 Mn. The company achieved a significant turnaround in profitability, posting a PAT of INR 37 Mn compared to a loss of INR 28 Mn in the same quarter last year. EBITDA saw a massive 314% YoY jump to INR 54 Mn, reflecting improved operational efficiency and a 10% margin. The company remains debt-free and continues to derive over 90% of its revenue from digital channels, supported by a cumulative customer base of 17.5 million.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 27% YoY to INR 540 Mn; 9M FY26 revenue reached INR 1,536 Mn.PAT turned positive at INR 37 Mn in Q3 FY26, a 233% increase from a loss of INR 28 Mn in Q3 FY25.EBITDA for Q3 FY26 stood at INR 54 Mn (10% margin) compared to INR 25.4 Mn in the previous year.The company is debt-free with a healthy current ratio of 9.6 and a cumulative customer base of 17.5 million.Digital-first strategy remains dominant with over 90% of revenue generated through online sales.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant turnaround in profitability and the company's successful transition to a higher-margin, asset-light model. Monitor the progress of the delayed Punjab manufacturing site and the monetization of the 'Dr Trust 360' app as future growth drivers.
Nureca Reports Q3 FY26 Revenue Growth of 27% YoY and PAT Turnaround to INR 37 Mn
Nureca Limited reported a strong Q3 FY26 with revenue increasing 27% YoY to INR 540 Mn and a significant turnaround in profitability, posting a PAT of INR 37 Mn compared to a loss in the previous year. The company continues to dominate the digital healthcare space with over 90% of revenue generated through online sales and a cumulative customer base of 17.5 million. EBITDA grew substantially to INR 54 Mn, reflecting a 113% increase over the previous year's quarter. The company remains debt-free with a healthy liquidity position, although its new manufacturing site in Punjab faces delays due to statutory approvals.
முக்கிய அம்சங்கள்
Revenue for Q3 FY26 grew 27% YoY to INR 540 Mn, while 9M FY26 revenue reached INR 1,536 Mn.Achieved a PAT of INR 37 Mn in Q3 FY26, a sharp recovery from a loss of INR 28 Mn in Q3 FY25.Gross Profit surged 50% YoY to INR 396 Mn, driven by strong brand equity of 'Dr Trust' and digital-first efficiency.Maintains a debt-free balance sheet with a cumulative customer base of 17.5 million users.New manufacturing facility at Sundran, Punjab is currently delayed pending statutory approvals.
👀 கவனிக்க வேண்டியவை
Investors should view the turnaround to profitability and strong revenue growth as a positive sign of operational efficiency. Monitor the progress of the Punjab manufacturing facility and the company's ability to scale its 'Dr Trust 360' connected health ecosystem.
Nureca Q3 FY26 Results: Revenue Up 50% YoY, PAT Turns Positive at ₹3.7 Cr
Nureca Limited reported a strong Q3 FY26 with revenue rising 50% YoY to ₹39.6 crore. The company successfully turned around its bottom line, posting a PAT of ₹3.7 crore against a loss of ₹2.8 crore in Q3 FY25. For the 9M FY26 period, revenue grew 43% to ₹111.6 crore, and PAT surged 604% to ₹8.2 crore. This performance was driven by sourcing efficiencies, cost optimization, and improved manufacturing capabilities.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 50% YoY to ₹39.6 crore compared to ₹26.5 crore in Q3 FY25Operating profit for Q3 FY26 stood at ₹3.3 crore, a 181% recovery from a loss of ₹4.0 crore9M FY26 PAT increased by 604% YoY to ₹8.2 crore from a loss of ₹1.6 croreSequential revenue growth was 5% QoQ, indicating steady momentumManagement highlights cost optimization and supply chain controls as key margin drivers
👀 கவனிக்க வேண்டியவை
Nureca has demonstrated a sharp recovery in profitability and strong top-line growth. Investors should watch for the sustainability of these margins as the company scales its manufacturing and sourcing operations.
Nureca Q3FY26 Results: Consolidated PAT Rises 33% to ₹37.3M; Revenue Up 57% YoY
Nureca Limited reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 57.3% YoY to ₹416.22 million. The company's consolidated profit after tax increased to ₹37.34 million from ₹28.01 million in the same quarter last year. On a standalone basis, the company achieved a significant turnaround, posting a profit of ₹32.31 million compared to a loss of ₹32.89 million in Q3FY25. Additionally, the company successfully completed a share buyback worth ₹19.14 crore at ₹330 per share during the quarter.
முக்கிய அம்சங்கள்
Consolidated revenue from operations surged 57.3% YoY to ₹416.22 million in Q3FY26.Consolidated PAT grew by 33.3% YoY to ₹37.34 million, with EPS rising to ₹3.91 from ₹2.80.Standalone results showed a major turnaround with a profit of ₹32.31 million vs a loss of ₹32.89 million YoY.Completed a ₹19.14 crore buyback at ₹330 per share, resulting in the extinguishment of shares during the quarter.Ongoing merger with subsidiary Nureca Technologies Private Limited is set for an effective date of April 1, 2025.
👀 கவனிக்க வேண்டியவை
The strong revenue growth and turnaround in standalone profitability indicate improving operational efficiency and demand. Investors should monitor the progress of the subsidiary merger and the impact of the reduced share capital on future EPS.
Nureca Completes Extinguishment of 4.58 Lakh Shares Following ₹330/Share Buyback
Nureca Limited has successfully completed the extinguishment of 4,58,255 equity shares following its buyback via the tender offer route. The buyback was executed at a price of ₹330 per share, leading to a reduction in the total paid-up equity share capital by approximately 4.58%. Post-extinguishment, the total number of equity shares stands reduced at 95,41,920 from the previous 1,00,00,175 shares. This corporate action is now fully concluded in compliance with SEBI Buyback Regulations.
முக்கிய அம்சங்கள்
Extinguished 4,58,255 equity shares of face value ₹10 each on January 7, 2026.The buyback was conducted at a price of ₹330 per share through a tender offer mechanism.Total paid-up equity share capital decreased from ₹10.00 crore to ₹9.54 crore.The total number of outstanding equity shares reduced from 1,00,00,175 to 95,41,920.The buyback tendering period was open from December 18, 2025, to December 24, 2025.
👀 கவனிக்க வேண்டியவை
The reduction in the total share base is expected to be EPS-accretive for existing shareholders. Investors should look for improved return on equity (ROE) in upcoming financial statements due to the reduced capital base.
Nureca Receives Warning Letters from BSE and NSE for Regulatory Non-Compliance
Nureca Limited has been issued formal warning letters by both BSE and NSE for failing to comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company did not conduct any meeting of its Stakeholders Relationship Committee during the entire Financial Year 2024-25, violating Regulation 20(3A). While the company reports no immediate financial impact, the exchanges have warned that future lapses will be viewed seriously and could lead to further disciplinary action. The board is now required to review these warnings and implement corrective measures to ensure future compliance.
முக்கிய அம்சங்கள்
Received warning letters from BSE on January 06, 2026, and NSE on January 07, 2026.Non-compliance identified regarding Regulation 20(3A) of SEBI LODR for FY 2024-25.Zero meetings of the Stakeholders Relationship Committee were held during the specified financial year.Exchanges have advised the company to exercise due caution and initiate corrective steps immediately.Company states there is no quantifiable monetary impact on financial or operational activities currently.
👀 கவனிக்க வேண்டியவை
Investors should treat this as a red flag regarding the company's internal governance and compliance oversight. While there is no immediate fine, continued regulatory lapses could lead to stricter penalties or impact investor sentiment.
Nureca Limited Completes ₹19.14 Crore Share Buyback at ₹330 Per Share
Nureca Limited has issued a post-buyback public announcement following the completion of its share repurchase program via the tender offer route. The company bought back equity shares for an aggregate amount not exceeding ₹19.14 crores at a maximum price of ₹330 per share. The buyback process, managed by Mefcom Capital Markets Limited, followed the board's approval on November 28, 2025. This announcement marks the formal conclusion of the buyback exercise as per SEBI regulations.
முக்கிய அம்சங்கள்
Maximum buyback size of ₹19,14,00,000 (₹19.14 crores) excluding transaction costs.Buyback price set at a maximum of ₹330 per equity share with a face value of ₹10.The offer was executed through the tender offer mechanism via the stock exchange.Post-buyback public announcement was published on January 01, 2026, in major national newspapers.Mefcom Capital Markets Limited acted as the Manager to the Buyback Offer.
👀 கவனிக்க வேண்டியவை
Investors who participated in the tender offer should verify the credit of funds in their bank accounts. The reduction in equity capital post-buyback may marginally improve the company's Earnings Per Share (EPS) for remaining shareholders.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
